"Narcotic Antagonists" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Agents inhibiting the effect of narcotics on the central nervous system.
| Descriptor ID |
D009292
|
| MeSH Number(s) |
D27.505.696.543 D27.505.696.663.850.512 D27.505.954.427.550
|
| Concept/Terms |
Narcotic Antagonists- Narcotic Antagonists
- Antagonists, Narcotic
- Opioid Receptor Antagonists
- Antagonists, Opioid Receptor
- Receptor Antagonists, Opioid
- Opioid Antagonists
- Antagonists, Opioid
|
Below are MeSH descriptors whose meaning is more general than "Narcotic Antagonists".
Below are MeSH descriptors whose meaning is more specific than "Narcotic Antagonists".
This graph shows the total number of publications written about "Narcotic Antagonists" by people in this website by year, and whether "Narcotic Antagonists" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1995 | 3 | 0 | 3 |
| 1997 | 2 | 2 | 4 |
| 1998 | 3 | 1 | 4 |
| 1999 | 3 | 1 | 4 |
| 2000 | 2 | 1 | 3 |
| 2001 | 1 | 1 | 2 |
| 2002 | 0 | 2 | 2 |
| 2003 | 4 | 1 | 5 |
| 2004 | 2 | 1 | 3 |
| 2005 | 0 | 1 | 1 |
| 2006 | 1 | 1 | 2 |
| 2007 | 1 | 2 | 3 |
| 2008 | 2 | 1 | 3 |
| 2009 | 4 | 0 | 4 |
| 2010 | 0 | 1 | 1 |
| 2011 | 0 | 1 | 1 |
| 2012 | 1 | 1 | 2 |
| 2013 | 4 | 2 | 6 |
| 2014 | 2 | 0 | 2 |
| 2016 | 3 | 0 | 3 |
| 2017 | 0 | 1 | 1 |
| 2018 | 3 | 2 | 5 |
| 2019 | 1 | 1 | 2 |
| 2020 | 4 | 5 | 9 |
| 2021 | 0 | 1 | 1 |
| 2022 | 0 | 4 | 4 |
| 2024 | 1 | 3 | 4 |
| 2025 | 2 | 0 | 2 |
To return to the timeline,
click here.
Below are the most recent publications written about "Narcotic Antagonists" by people in Profiles.
-
Navacaprant, a Novel and Highly Selective Kappa Opioid Receptor Antagonist, in Adults With Major Depressive Disorder: A Randomized, Double-Blind Phase 2 Clinical Trial. J Clin Psychopharmacol. 2025 May-Jun 01; 45(3):267-276.
-
Concurrent Depression Management in Patients with Opioid Use Disorder Undergoing Buprenorphine Therapy: Association with Buprenorphine Discontinuation. J Dual Diagn. 2025 Apr; 21(2):142-151.
-
Understanding the financial barriers to treatment among individuals with opioid use disorder: a focus group study. Harm Reduct J. 2024 Dec 20; 21(1):220.
-
Emergency Department Patients with Para-Fluorofentanyl Overdose. J Emerg Med. 2025 May; 72:56-69.
-
Perceptions Toward Naloxone Among Patients With Cancer Receiving Opioids. J Pain Symptom Manage. 2024 Dec; 68(6):e500-e507.
-
Disposition Outcomes Following Prehospital Use of Naloxone in a Large Metropolitan City in the United States. Prehosp Emerg Care. 2025; 29(4):361-366.
-
96-week retention in treatment with extended-release subcutaneous buprenorphine depot injections among people with opioid dependence: Extended follow-up after a single-arm trial. Int J Drug Policy. 2024 May; 127:104390.
-
Patients' willingness to pay for naloxone: A national cross-sectional survey of prescription opioid users with chronic pain in the United States. J Am Pharm Assoc (2003). 2024 May-Jun; 64(3):102062.
-
Efforts to Improve Naloxone Co-Prescription for Patients With Cancer Pain at Risk of Opioid Overdose. J Palliat Med. 2023 07; 26(7):969-973.
-
Naloxone Over the Counter: Increasing Opportunities and Challenges for Health Providers. Am J Med. 2023 06; 136(6):504-506.